中国抗癌协会会员；

中国研究型医院学会甲状腺专业委员会临床研究学组成员；

四川省肿瘤学会会员；

中国抗癌协会肿瘤标志专业委员会 甲状腺癌标志物协作组委员

研究方向是抗肿瘤子化合物的药理和药效研究，相关研究成果以第一作者或通讯作者在PNAS, Sci. Adv., Phytomedicine，J. Med. Chem., Cell Death Dis.，Biomaterials等杂志上发表高水平论文40余篇；主持包括国家自然基金，中国博士后基金，四川省科技厅项目等10余项科研课题；参与国家一类新药研发项目“治疗并增强肺癌化疗药物敏感的注射用和厚朴酚脂质体冻干粉”的开发，主要负责注射用和厚朴酚脂质体冻干粉的药理药效研究；获得国家发明授权专利3项。

近期代表性成果（*标注为通讯作者）：

1. Zhichao Xing, Xiaoying Cai, Ting He, Peiheng Li, Jun He, Yuxuan Qiu, Na Li, Li Mi, Ruixi Li, Jingqiang Zhu, Zhihui Li*, Anping Su*, Haoyu Ye*, Wenshuang Wu*. VCP’s nuclear journey: Initiated by interacting with KPNB1 to repair DNA damage. Proc Natl Acad Sci U S A. 2025 May 13;122(19):e2416045122.

2. Kaiyue Su, Neng Ye, Lei Lin, Jie Wu, Min Zhao, Xueqin Jiang, Ruijia Zhang, Xiaoying Cai, Xinlu Zhang, Jing Peng, Minghai Tang, Na Li, Lijuan Chen, Haoyu Ye*, Wenshuang Wu*. Valtrate alleviates inflammation by targeting USP9X to enhance NLRP3 degradation. Phytomedicine. 2025 Jul 25:143:156835.

3.  Yujie Zhang, Tianyou Liu, Pengyu Li, Zhichao Xing, Li Mi, Ting He, Tao Wei*, Wenshuang Wu*. Potential therapeutic targets of eukaryotic translation initiation factors in tumor therapy. Eur J Med Chem. 2025 Jul 5;291:117638.

4. Ruixi Li, Ting He, Zhichao Xing, Li Mi, Anping Su, Wenshuang Wu*. The immune system in Hashimoto's thyroiditis: Updating the current state of knowledge on potential therapies and animal model construction. Autoimmun Rev. 2025 Mar 30;24(6):103783.

5. Liqin Liu, Zhihui Li*, Wenshuang Wu*. Harnessing natural inhibitors of protein synthesis for cancer therapy: A comprehensive review. Pharmacol Res. 2024 Oct 4;209:107449.

6. Li Mi, Jiaye Liu, Yujie Zhang, Anping Su, Minghai Tang, Zhichao Xing, Ting He, Tao Wei, Zhihui Li*, Wenshuang Wu*. The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy. Phytomedicine. 2024 Jul;129:155670.

7. Min Zhao, Neng Ye, Ling Liu, Ruijia Zhang, Na Li, Jing Peng, Xiaoying Cai, Xueqin Jiang, Kaiyue Su, Xinlu Zhang, Qianru Rao, Kongjun Liu, Dexin Deng, Aihua Peng, Minghai Tang, Lijuan Chen, Wenshuang Wu*, Haoyu Ye*. Novel Isoalantolactone-Based Derivatives as Potent NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization. J Med Chem. 2024 May 9;67(9):7516-7538.

8. Xueqin Jiang, Xinlu Zhang, Xiaoying Cai, Na Li, Hongyu Zheng, Minghai Tang, Jiangli Zhu, Kaiyue Su, Ruijia Zhang, Neng Ye, Jing Peng, Min Zhao, Wenshuang Wu*, Jianhong Yang*, Haoyu Ye*. NU6300 covalently reacts with cysteine-191 of gasdermin D to block its cleavage and palmitoylation. Sci Adv. 2024;10(6):eadi9284.

9. Na Li, Ruijia Zhang, Minghai Tang, Min Zhao, Xueqin Jiang, Xiaoying Cai, Neng Ye, Kaiyue Su, Jing Peng, Xinlu Zhang, Wenshuang Wu*, Haoyu Ye*. Recent Progress and Prospects of Small Molecules for NLRP3 Inflammasome Inhibition. J Med Chem. 2023 Nov 9;66(21):14447-14473.

10. Na Li, Xueqin Jiang, Ruijia Zhang, Neng Ye, Minghai Tang, Xiaoying Cai, Kaiyue Su, Jing Peng, Xinlu Zhang, Min Zhao, Wenshuang Wu*, Haoyu Ye*. Discovery of Triazinone Derivatives as Novel, Specific, and Direct NLRP3 Inflammasome Inhibitors for the Treatment of DSS-Induced Ulcerative Colitis. J Med Chem. 2023 Oct 12;66(19):13428-13451.  

11. Ruijia Zhang, Na Li, Min Zhao, Minghai Tang, Xueqin Jiang, Xiaoying Cai, Neng Ye, Kaiyue Su, Jing Peng, Xinlu Zhang, Wenshuang Wu*, Haoyu Ye*. From lead to clinic: A review of the structural design of P2X7R antagonists. Eur J Med Chem. 2023 May 5;251:115234.

12. Xiaoying Cai, Xueqin Jiang, Min Zhao, Kaiyue Su, Minghai Tang, Feng Hong, Neng Ye, Ruijia Zhang, Na Li, Lun Wang, Linlin Xue, Zejiang Zhu, Lijuan Chen, Jianhong Yang, Wenshuang Wu*, Haoyu Ye*. Identification of the target protein and molecular mechanism of honokiol in anti-inflammatory action. Phytomedicine. 2023 Jan;109:154617.